Rubicon Biotech Event Report

Abstract

Rubicon's Special Event Report offers independent, objective and insightful analysis into a specific event relating to a key drug product from Myogen, Inc. (MYOG) . The Event Reports from Rubicon Global Research typically analyze an upcoming FDA approval, an FDA panel meeting, the presentation of clinical data or any other unique event with the potential to influence the Company's business and valuation. The Rubicon report begins by identifying Myogen, Inc.'s business and particular drug in which a major event is expected. The report then includes a detailed discussion of the drug, the disease it treats, side effects, and competing therapeutic options. While the report will not provide a recommendation on the stock, it will provide an expected outcome (positive or negative) on the event, which can substantially impact the stock depending on the market size of the drug relative the Company's market cap. Additional content and features include other Individual Myogen, Inc. Product Lines and stage of development for each product in the pipeline, followed by summary financial data. The Rubicon Event Reports are an essential source of insight into specific drugs and key milestones or events that can create substantial value drivers for the stock price. The detailed discussion available in each report provide a rich and integrated information source for investment banking, corporate finance, C-level executives, management consultants, marketing, and business intelligence professionals who want actionable answers and ideas in seconds.